Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge

dc.contributor.authorAbdelrahim, Maen
dc.contributor.authorEsmail, Abdullah
dc.contributor.authorAl Saadi, Noor
dc.contributor.authorZsigmond, Eva
dc.contributor.authorAl Najjar, Ebtesam
dc.contributor.authorBugazia, Doaa
dc.contributor.authorAl-Rawi, Hadeel
dc.contributor.authorAlsaadi, Ayat
dc.contributor.authorKaseb, Ahmed O.
dc.date.accessioned2026-10-23T21:14:45Z
dc.date.issued2022
dc.description.abstractThe COVID-19 pandemic has impacted every country in the world. With more than 400 million cases and more than 5.5 million deaths. The FDA either approved or authorized the emergency use for three vaccines against COVID-19. The treatment options of COVID-19 are very limited. Multiple complementary and alternative medicine modalities were suggested to be efficacious in the treatment of COVID-19 such as Thymoquinone. The effects of Thymoquinone have been examined and multiple studies indicate a promising beneficial effect. However, the current body of research is limited in terms of its scope, quality, and quantity. While higher-quality studies are required, physicians do not routinely recommend the use of marketed supplements of natural products, including Thymoquinone for COVID-19. Given the numerous suggested positive effects of Thymoquinone, including anti-inflammatory and antimicrobial properties, additional research is required to confirm or refute these promising benefits. Complementary and alternative medicine is an area that requires additional evidence-based practice and research to confirm effects observed in clinical practice.
dc.identifier.citationAbdelrahim, M., Esmail, A., Al Saadi, N., Zsigmond, E., Al Najjar, E., Bugazia, D., Al-Rawi, H., Alsaadi, A., & Kaseb, A. O. (2022). Thymoquinone's antiviral effects: It is time to be proven in the Covid-19 pandemic era and its Omicron variant surge. Frontiers in Pharmacology, 13, Article 848676. https://doi.org/10.3389/fphar.2022.848676
dc.identifier.doi10.3389/fphar.2022.848676
dc.identifier.issn1663-9812
dc.identifier.urihttps://doi.org/10.3389/fphar.2022.848676
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fphar.2022.848676/full
dc.identifier.urihttps://repository.ust.edu.ye/handle/123456789/3034
dc.language.isoen
dc.publisherFrontiers Media SA
dc.relation.ispartofFrontiers in Pharmacology
dc.subjectCoronavirus
dc.subjectPandemic
dc.subjectThymoquinone
dc.subjectCovid-19
dc.subjectMolnupiravir
dc.subjectPaxlovid
dc.subjectOmicron Variant
dc.subjectCovid-19 Vaccines And Anti-Viral Agents
dc.titleThymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
dc.typeArticle

ملفات